Indivior PLC (INDVL.XC)
| Previous close | 1,448.00 |
| Open | 1,449.00 |
| Bid | 1,426.00 x N/A |
| Ask | 1,428.00 x N/A |
| Day's range | 1,412.00 - 1,452.00 |
| 52-week range | 1,128.00 - 1,926.00 |
| Volume | |
| Avg. volume | 92,754 |
| Market cap | 1.919B |
| Beta (5Y monthly) | 0.06 |
| PE ratio (TTM) | 47,466.67 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 16 Jun 2016 |
| 1y target est | N/A |
- PR Newswire
Indivior to Host Analyst Teach-in Event in New York City; Reconfirms Full Year 2024 Guidance
Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, announced that in anticipation of the expected primary listing of the Company's shares on Nasdaq , members of Indivior's senior leadership team will be hosting an analyst teach-in event today in New York City. The event, which will be webcast (see details below), is intended to provide an in-depth overview of Indivior's growth and value creation path. During the event, the Company will reconfirm its unchanged FY 2024
- PR Newswire
Indivior Announces Q1 2024 Financial Results
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com.
- PR Newswire
Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone
Indivior PLC (LSE/Nasdaq: INDV) today announced results from a pharmacodynamic study demonstrating that OPVEE® rapidly reverses opioid-induced respiratory depression, which is the major cause of deaths due to opioid overdose. The study, "Reversal of opioid-induced respiratory depression in healthy volunteers: comparison of intranasal nalmefene and intranasal naloxone", was published in the Journal of Clinical Pharmacology (Reversal of Opioid‐Induced Respiratory Depression in Healthy Volunteers:
